Search

Your search keyword '"Moller, Jacob Eifer"' showing total 115 results
Start Over Author "Moller, Jacob Eifer"
115 results on '"Moller, Jacob Eifer"'

4. Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program

Author

Andersen, Camilla Fuchs, Larsen, Julie Hempel, Jensen, Jesper, Omar, Massar, Nouhravesh, Nina, Kistorp, Caroline, Tuxen, Christian, Gustafsson, Finn, Knop, Filip K., Forman, Julie Lyng, Davidovski, Filip Soeskov, Jensen, Lars Thorbjørn, Højlund, Kurt, Køber, Lars, Antonsen, Lisbeth, Poulsen, Mikael Kjær, Schou, Morten, and Møller, Jacob Eifer

Published
2024
Full Text
View/download PDF

5. Health-related quality of life and cognitive function after out-of-hospital cardiac arrest; a comparison of prehospital return-of-spontaneous circulation and refractory arrest managed with extracorporeal cardiopulmonary resuscitation

Author

Gregers, Emilie, Linde, Louise, Kunkel, Joakim Bo, Wiberg, Sebastian, Møller-Sørensen, Peter Hasse, Smerup, Morten, Borregaard, Britt, Schmidt, Henrik, Lassen, Jens Flensted, Møller, Jacob Eifer, Hassager, Christian, Søholm, Helle, and Kjærgaard, Jesper

Published
2024
Full Text
View/download PDF

6. NatIonal Danish endocarditis stUdieS – Design and objectives of the NIDUS registry

Author

Graversen, Peter L., Hadji-Turdeghal, Katra, Møller, Jacob Eifer, Bruun, Niels Eske, Laghmoch, Hicham, Jensen, Andreas Dalsgaard, Petersen, Jeppe K., Bundgaard, Henning, Iversen, Kasper, Povlsen, Jonas A., Moser, Claus, Smerup, Morten, Jensen, Hanne Sortsøe, Søgaard, Peter, Helweg-Larsen, Jannik, Faurholt-Jepsen, Daniel, Østergaard, Lauge, Køber, Lars, and Fosbøl, Emil L.

Published
2024
Full Text
View/download PDF

8. Treatment effects of blood pressure targets and hemodynamics according to initial blood lactate levels in comatose out-of-hospital cardiac arrest patients – A sub study of the BOX trial

Author

Beske, Rasmus P., Søndergaard, Frederik T., Møller, Jacob Eifer, Schmidt, Henrik, Kjaergaard, Jesper, Obling, Laust, Meyer, Martin A.S., Mølstrøm, Simon, Winther-Jensen, Matilde, Højgaard, Henrik Frederiksen, Jeppesen, Karoline Korsholm, Sarkisian, Laura, Grand, Johannes, and Hassager, Christian

Published
2024
Full Text
View/download PDF

15. Hyperlactataemia is a marker of reduced exercise capacity in heart failure with preserved ejection fraction.

Author

Nan Tie, Emilia, Wolsk, Emil, Nanayakkara, Shane, Vizi, Donna, Mariani, Justin, Moller, Jacob Eifer, Hassager, Christian, Gustafsson, Finn, and Kaye, David M.

Subjects
BLOOD lactate, AEROBIC capacity, CHRONIC kidney failure, HEART failure, CARDIAC catheterization
Abstract

Aims: Heart failure with preserved ejection fraction (HFpEF) is associated with an array of central and peripheral haemodynamic and metabolic changes. The exact pathogenesis of exercise limitation in HFpEF remains uncertain. Our aim was to compare lactate accumulation and central haemodynamic responses to exercise in patients with HFpEF, non‐cardiac dyspnoea (NCD), and healthy volunteers. Methods and results: Right heart catheterization with mixed venous blood gas and lactate measurements was performed at rest and during symptom‐limited supine exercise. Multivariable analyses were conducted to determine the relationship between haemodynamic and biochemical parameters and their association with exercise capacity. Of 362 subjects, 198 (55%) had HFpEF, 103 (28%) had NCD, and 61 (17%) were healthy volunteers. This included 139 (70%) females with HFpEF, 77 (75%) in NCD (P = 0.41 HFpEF vs. NCD), and 31 (51%) in healthy volunteers (P < 0.001 HFpEF vs. volunteers). The median age was 71 (65, 75) years in HFpEF, 66 (57, 72) years in NCD, and 49 (38, 65) years in healthy volunteers (HFpEF vs. NCD or volunteer, both P < 0.001). Peak workload was lower in HFpEF compared with healthy volunteers [52 W (interquartile range 31–73), 150 W (125–175), P < 0.001], but not NCD [53 W (33, 75), P = 0.85]. Exercise lactate indexed to workload was higher in HFpEF at 0.08 mmol/L/W (0.05–0.11), 0.06 mmol/L/W (0.05–0.08; P = 0.016) in NCD, and 0.04 mmol/L/W (0.03–0.05; P < 0.001) in volunteers. Exercise cardiac index was 4.5 L/min/m2 (3.7–5.5) in HFpEF, 5.2 L/min/m2 (4.3–6.2; P < 0.001) in NCD, and 9.1 L/min/m2 (8.0–9.9; P < 0.001) in volunteers. Oxygen delivery in HFpEF was lower at 1553 mL/min (1175–1986) vs. 1758 mL/min (1361–2282; P = 0.024) in NCD and 3117 mL/min (2667–3502; P < 0.001) in the volunteer group during exercise. Predictors of higher exercise lactate levels in HFpEF following adjustment included female sex and chronic kidney disease (both P < 0.001). Conclusions: HFpEF is associated with reduced exercise capacity secondary to both central and peripheral factors that alter oxygen utilization. This results in hyperlactataemia. In HFpEF, plasma lactate responses to exercise may be a marker of haemodynamic and cardiometabolic derangements and represent an important target for future potential therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Association between speckle tracking echocardiography and pressure-volume loops during cardiogenic shock development

Author

Frederiksen, Peter Hartmund, primary, Linde, Louise, additional, Gregers, Emilie, additional, Udesen, Nanna Louise Junker, additional, Helgestad, Ole K, additional, Banke, Ann, additional, Dahl, Jordi Sanchez, additional, Povlsen, Amalie L, additional, Jensen, Lisette Okkels, additional, Larsen, Jeppe P, additional, Lassen, Jens, additional, Schmidt, Henrik, additional, Ravn, Hanne Berg, additional, and Moller, Jacob Eifer, additional

Published
2024
Full Text
View/download PDF

22. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial

Author

Jensen, Jesper, Omar, Massar, Kistorp, Caroline, Tuxen, Christian, Gustafsson, Ida, Køber, Lars, Gustafsson, Finn, Faber, Jens, Malik, Mariam Elmegaard, Fosbøl, Emil Loldrup, Bruun, Niels Eske, Forman, Julie Lyng, Jensen, Lars Thorbjørn, Møller, Jacob Eifer, and Schou, Morten

Published
2021
Full Text
View/download PDF

24. Glimpse into the future

Author

Moller, Jacob Eifer, primary, Mangner, Norman, additional, Pappalardo, Federico, additional, and Thiele, Holger, additional

Published
2023
Full Text
View/download PDF

26. The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure

Author

Vetrovec, George W., Anderson, Mark, Schreiber, Theodore, Popma, Jeffrey, Lombardi, William, Maini, Brijeshwar, Moller, Jacob Eifer, Schäfer, Andreas, Dixon, Simon R., Hall, Shelley, Ohman, E. Magnus, Mindrescu, Catalin, Moses, Jeffrey, and O'Neill, William

Published
2018
Full Text
View/download PDF

29. Current and future trial design in refractory cardiogenic shock

Author

Arrigo, Mattia, primary, Blet, Alice, additional, Morley‐Smith, Andrew, additional, Aissaoui, Nadia, additional, Baran, David A., additional, Bayes‐Genis, Antoni, additional, Chioncel, Ovidiu, additional, Desch, Steffen, additional, Karakas, Mahir, additional, Moller, Jacob Eifer, additional, Poess, Janine, additional, Price, Susanna, additional, Zeymer, Uwe, additional, and Mebazaa, Alexandre, additional

Published
2023
Full Text
View/download PDF

30. Selection of patients for mechanical circulatory support for refractory out-of-hospital cardiac arrest

Author

Linde, Louise, Mørk, Sivagowry Rasalingam, Gregers, Emilie, Andreasen, Jo Bønding, Lassen, Jens Flensted, Ravn, Hanne Berg, Schmidt, Henrik, Riber, Lars Peter, Thomassen, Sisse Anette, Laugesen, Helle, Eiskjær, Hans, Terkelsen, Christian Juhl, Christensen, Steffen, Tang, Mariann, Moeller-Soerensen, Hasse, Holmvang, Lene, Kjaergaard, Jesper, Hassager, Christian, Moller, Jacob Eifer, Linde, Louise, Mørk, Sivagowry Rasalingam, Gregers, Emilie, Andreasen, Jo Bønding, Lassen, Jens Flensted, Ravn, Hanne Berg, Schmidt, Henrik, Riber, Lars Peter, Thomassen, Sisse Anette, Laugesen, Helle, Eiskjær, Hans, Terkelsen, Christian Juhl, Christensen, Steffen, Tang, Mariann, Moeller-Soerensen, Hasse, Holmvang, Lene, Kjaergaard, Jesper, Hassager, Christian, and Moller, Jacob Eifer

Abstract

Objective: To describe characteristics of patients admitted with refractory cardiac arrest for possible extracorporeal cardiopulmonary resuscitation (ECPR) and gain insight into the reasons for refraining from treatment in some. Methods: Nationwide retrospective cohort study involving all tertiary centres providing ECPR in Denmark. Consecutive patients admitted with ongoing chest compression for evaluation for ECPR treatment were enrolled. Presenting characteristics, duration of no-flow and low-flow time, end-tidal carbon dioxide (ETCO2), lactate and pH, and recording of reasons for refraining from ECPR documented by the treating team were recorded. Outcomes were survival to intensive care unit admission and survival to hospital discharge. Results: Of 579 patients admitted with refractory cardiac arrest for possible ECPR, 221 patients (38%) proceeded to ECPR and 358 patients (62%) were not considered candidates. Median prehospital low-flow time was 70 min (IQR 56 to 85) in ECPR patients and 62 min (48 to 81) in no-ECPR patients, p<0.001. Intra-arrest transport was more than 50 km in 92 (42%) ECPR patients and 135 in no-ECPR patients (38%), p=0.25. The leading causes for not initiating ECPR stated by the treating team were duration of low-flow time in 39%, severe metabolic derangement in 35%, and in 31% low ETCO2. The prevailing combination of contributing factors were non-shockable rhythm, low ETCO2, and metabolic derangement or prehospital low-flow time combined with low ETCO2. Survival to discharge was only achieved in six patients (1.7%) in the no-ECPR group. Conclusions: In this large nationwide study of patients admitted for possible ECPR, two-thirds of patients were not treated with ECPR. The most frequent reasons to abstain from ECPR were long duration of prehospital low-flow time, metabolic derangement and low ETCO2.

Published
2023

36. Selection of patients for mechanical circulatory support for refractory out-of-hospital cardiac arrest

Author

Linde, Louise, primary, Mørk, Sivagowry Rasalingam, additional, Gregers, Emilie, additional, Andreasen, Jo Bønding, additional, Lassen, Jens Flensted, additional, Ravn, Hanne Berg, additional, Schmidt, Henrik, additional, Riber, Lars Peter, additional, Thomassen, Sisse Anette, additional, Laugesen, Helle, additional, Eiskjær, Hans, additional, Terkelsen, Christian Juhl, additional, Christensen, Steffen, additional, Tang, Mariann, additional, Moeller-Soerensen, Hasse, additional, Holmvang, Lene, additional, Kjaergaard, Jesper, additional, Hassager, Christian, additional, and Moller, Jacob Eifer, additional

Published
2022
Full Text
View/download PDF

38. Association between inflammatory markers and survival in comatose, resuscitated out-of-hospital cardiac arrest patients

Author

Pedersen, Anne Toftgaard, Kjaergaard, Jesper, Hassager, Christian, Frydland, Martin, Thomsen, Jakob Hartvig, Klein, Anika, Schmidt, Henrik, Moller, Jacob Eifer, Wiberg, Sebastian, Pedersen, Anne Toftgaard, Kjaergaard, Jesper, Hassager, Christian, Frydland, Martin, Thomsen, Jakob Hartvig, Klein, Anika, Schmidt, Henrik, Moller, Jacob Eifer, and Wiberg, Sebastian

Abstract

Objectives: Prognostication after out-of-hospital cardiac arrest (OHCA) remains challenging. The inflammatory response after OHCA has been associated with increased mortality. This study investigates the associations and predictive value between inflammatory markers and outcome in resuscitated OHCA patients.Design: The study is based on post hoc analyses of a double-blind controlled trial, where resuscitated OHCA patients were randomized to receive either exenatide or placebo. Blood was analyzed for levels of inflammatory markers the day following admission. Primary endpoint was time to death for up to 180-days. Secondary endpoints included 180-day mortality and poor neurological outcome after 180-days, defined as a cerebral performance category (CPC) of 3 to 5.Results: Among 110 included patients we found significant associations between higher leucocyte quartile and increasing mortality in univariable analysis (OR 2.6 (95%CI 1.6-4.2), pConclusions: Total leucocyte count and neutrophil levels measured the first day following OHCA were significantly associated with 180-day all-cause mortality and may potentially act as early predictors of outcome.

Published
2022

44. Five-year risk of heart failure and death following myocardial infarction with cardiogenic shock: a nationwide cohort study

Author

Lauridsen, Marie Dam, Rorth, Rasmus, Butt, Jawad Haider, Kristensen, Soren Lund, Schmidt, Morten, Moller, Jacob Eifer, Hassager, Christian, Torp-pedersen, Christian, Gislason, Gunnar, Kober, Lars, Fosbol, Emil Loldrup, Lauridsen, Marie Dam, Rorth, Rasmus, Butt, Jawad Haider, Kristensen, Soren Lund, Schmidt, Morten, Moller, Jacob Eifer, Hassager, Christian, Torp-pedersen, Christian, Gislason, Gunnar, Kober, Lars, and Fosbol, Emil Loldrup

Published
2021

45. Treatment Effects of Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest (The IMICA Trial) A Double-Blinded, Placebo-Controlled, Single-Center, Randomized, Clinical Trial

Author

Meyer, Martin Abild Stengaard, Wiberg, Sebastian, Grand, Johannes, Meyer, Anna Sina Pettersson, Obling, Laust Emil Roelsgaard, Frydland, Martin, Thomsen, Jakob Hartvig, Josiassen, Jakob, Moller, Jacob Eifer, Kjaergaard, Jesper, Hassager, Christian, Meyer, Martin Abild Stengaard, Wiberg, Sebastian, Grand, Johannes, Meyer, Anna Sina Pettersson, Obling, Laust Emil Roelsgaard, Frydland, Martin, Thomsen, Jakob Hartvig, Josiassen, Jakob, Moller, Jacob Eifer, Kjaergaard, Jesper, and Hassager, Christian

Abstract

Background: Patients experiencing out-of-hospital cardiac arrest who remain comatose after initial resuscitation are at high risk of morbidity and mortality attributable to the ensuing post–cardiac arrest syndrome. Systemic inflammation constitutes a major component of post–cardiac arrest syndrome, and IL-6 (interleukin-6) levels are associated with post–cardiac arrest syndrome severity. The IL-6 receptor antagonist tocilizumab could potentially dampen inflammation in post–cardiac arrest syndrome. The objective of the present trial was to determine the efficacy of tocilizumab to reduce systemic inflammation after out-of-hospital cardiac arrest of a presumed cardiac cause and thereby potentially mitigate organ injury. Methods: Eighty comatose patients with out-of-hospital cardiac arrest were randomly assigned 1:1 in a double-blinded placebo-controlled trial to a single infusion of tocilizumab or placebo in addition to standard of care including targeted temperature management. Blood samples were sequentially drawn during the initial 72 hours. The primary end point was the reduction in C-reactive protein response from baseline until 72 hours in patients treated with tocilizumab evaluated by mixed-model analysis for a treatment-by-time interaction. Secondary end points (main) were the marker of inflammation: leukocytes; the markers of myocardial injury: creatine kinase myocardial band, troponin T, and N-terminal pro B-type natriuretic peptide; and the marker of brain injury: neuron-specific enolase. These secondary end points were analyzed by mixed-model analysis. Results: The primary end point of reducing the C-reactive protein response by tocilizumab was achieved since there was a significant treatment-by-time interaction, P<0.0001, and a profound effect on C-reactive protein levels. Systemic inflammation was reduced by treatment with tocilizumab because both C-reactive protein and leukocyte levels were markedly reduced, tocilizumab versus placebo at 24 hours: –84

Published
2021

46. 287 Association of lactate and lactate clearance with favourable neurological outcome in cardiac arrest patients managed with extracorporeal cardiopulmonary resuscitation

Author

Gregers, Emilie, Thevathasan, Tharusan, Mørk, Sivagowry Rasalingam, Linde, Louise, Andreasen, Jo Bønding, Degbeon, Sêhnou, Smerup, Morten Holdgaard, Hassager, Christian, Møller, Jacob Eifer, Laugesen, Helle, Terkelsen, Christian Juhl, Lassen, Jens Flensted, Søholm, Helle, and Skurk, Carsten

Published
2023
Full Text
View/download PDF

47. Contemporary trends in use of mechanical circulatory support in patients with acute MI and cardiogenic shock

Author

Helgestad, Ole Kristian Lerche, Josiassen, Jakob, Hassager, Christian, Jensen, Lisette Okkels, Holmvang, Lene, Udesen, Nanna Louise Junker, Schmidt, Henrik, Berg Ravn, Hanne, Moller, Jacob Eifer, Helgestad, Ole Kristian Lerche, Josiassen, Jakob, Hassager, Christian, Jensen, Lisette Okkels, Holmvang, Lene, Udesen, Nanna Louise Junker, Schmidt, Henrik, Berg Ravn, Hanne, and Moller, Jacob Eifer

Abstract

Objectives To describe the contemporary trends in the use of mechanical circulatory support (MCS) in patients with acute myocardial infarction and cardiogenic shock (AMICS). To evaluate survival benefit with early application of intra-aortic balloon pump (IABP) or Impella CP. Methods A cohort study of all consecutive patients with AMICS undergoing percutaneous coronary intervention (PCI) <24 hours of symptom onset (early PCI) in southeastern Denmark from 2010 to 2017. A matched case-control study comparing 30-day mortality between patients receiving early-IABP or early-Impella CP and their respective control group. Controls were matched on age, left ventricular ejection fraction, arterial lactate, estimated glomerular filtration rate and cardiac arrest before PCI. Early-IABP/Impella CP was defined as applied before PCI if shock developed pre-PCI, or immediately after PCI if shock developed during PCI. Results 903 patients with AMICS undergoing early PCI were identified. Use of MCS decreased from 50% in 2010 to 25% in 2017, p for trend of <0.001. The IABP was abandoned in 2012 and replaced mostly by Impella CP. Patients receiving MCS in 2013-2017 had more compromised haemodynamics compared with patients receiving MCS in 2010-2012. 40 patients received early IABP, and 40 patients received early Impella CP. Only the group receiving early Impella CP was associated with lower 30-day mortality compared with their matched control group (30-day mortality 40% vs 77.5%, plog-rank of<0.001). Conclusion Use of MCS decreased by 50% from 2010 to 2017. Patients receiving MCS had more compromised haemodynamics in recent years. Early application of Impella CP was associated with reduced 30-day mortality compared with a matched control group.

Published
2020

50. Five-year risk of heart failure and death following myocardial infarction with cardiogenic shock: a nationwide cohort study

Author

Lauridsen, Marie Dam, primary, Rorth, Rasmus, additional, Butt, Jawad Haider, additional, Kristensen, Soren Lund, additional, Schmidt, Morten, additional, Moller, Jacob Eifer, additional, Hassager, Christian, additional, Torp-Pedersen, Christian, additional, Gislason, Gunnar, additional, Kober, Lars, additional, and Fosbol, Emil Loldrup, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results